Ann Pediatr Endocrinol Metab.  2025 Feb;30(1):45-47. 10.6065/apem.2448032.016.

Diagnostic challenges of Allan-Herndon-Dudley syndrome: a case of hypothyroidism and developmental delay

• Joo EY
• Yoo MJ
• Lee JE
• Kim SJ

• KMID: 2565216
• DOI: http://doi.org/10.6065/apem.2448032.016

Reference

References

1. Schwartz CE, Stevenson RE. The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome. Best Pract Res Clin Endocrinol Metab. 2007; 21:307–21.

2. Herzovich V, Vaiani E, Marino R, Dratler G, Lazzati J, Tilitzky S, et al. Unexpected peripheral markers of thyroid function in a patient with a novel mutation of the MCT8 thyroid hormone transporter gene. Horm Res. 2007; 67:1–6.

3. Remerand G, Boespflug-Tanguy O, Tonduti D, Touraine R, Rodriguez D, Curie A, et al. Expanding the phenotypic spectrum of Allan-Herndon-Dudley syndrome in patients with SLC16A2 mutations. Dev Med Child Neurol. 2019; 61:1439–47.

4. Han JY, Lee S, Woo H, Kim SY, Kim H, Lim BC, et al. Heterogeneous clinical characteristics of Allan-Herndon-Dudley syndrome with SLC16A2 mutations. Ann Child Neurol. 2021; 29:149–58.

5. Sarret C, Oliver Petit I, Tonduti D. Allan-Herndon-Dudley syndrome. 2010 Mar 9 [updated 2020 Jan 16]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26373.

6. Vancamp P, Demeneix BA, Remaud S. Monocarboxylate transporter 8 deficiency: delayed or permanent hypomyelination? Front Endocrinol (Lausanne). 2020; 11:283.

7. Bauer AJ. Triac in the treatment of Allan-Herndon-Dudley syndrome. Lancet Diabetes Endocrinol. 2019; 7:661–3.